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Abstract
Background Provider volume is often a central topic in
debates about centralization of procedures. In Norway, there
is considerable variation in provider volumes of the neuro-
surgical centers treating children. We sought to explore long-
term survival after surgery for central nervous system tumors
in children in relation to regional provider volumes.
Method Based on data from the Norwegian Cancer Registry
we analyzed survival in all reported central nervous system
tumors in children under the age of 16 treated over two
decades, between March 1988 and April 2008; a total of 816
patients with histologically confirmed disease.
Results There was no overall difference in survival between
regions. In the subgroup of PNET/medulloblastomas, both
livinginthehigh-providervolumehealthregionandreceiving
treatment in the high-volume region was significantly
associated with inferior survival.
Conclusions In this population-based study of children
operated over a period of two decades, we found no
evidence of improved long-term survival in the high-
provider volume region. Surprisingly, a subgroup analysis
indicated that survival in PNET/medulloblastomas was
significantly better if living outside the most populated
health region with the highest provider volumes. One
should, however, be careful of interpreting this directly as
a symptom of quality of care, as there may be unseen
confounders. Our study demonstrates that provider case
volume may serve as an axiom in debates about centrali-
zation of cancer surgery while perhaps much more reliable
and valid but less quantifiable factors are important for the
final results.
Keywords Brain neoplasms.Child.Hospital mortality/
trends.Survival analysis
Introduction
It has been demonstrated that high-volume centers and
surgeons may be associated with lower perioperative
mortality after major cancer surgery and a range of other
procedures [7], but the relative importance of volume varies
markedly in different publications and according to the type
of surgery [9, 13]. Moreover, several limitations are
common in such studies. Frequent limitations are failure
to control for potential confounders, lack of validated, long-
term end-points, and lack of analysis based on surgeons’
individual surgical volumes. Further, interest-bias may be
associated with such studies as publications mostly origi-
nate from high-volume centers. Finally, as the majority of
the available studies are American, the results may not
necessarily directly apply to countries where health care is
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analysis of 101 publications found that one-third of the
included studies did not find an effect of volume on
mortality. The heterogeneity of results made the authors
question the value of case volume as a proxy for care
quality [12].
Norway has a population of 4.7 million people and a
socialized health care system having quite evenly
distributed resources and uniform training and licensing
for medical professionals. Due to considerable regional
differences in provider volumes, a centralization of
pediatric neurosurgery has been debated for years.
However, so far, surgery is provided by pediatric neuro-
surgeons at four different university hospitals, each
serving a separate geographical health region. As the
southeastern region is by far the most populated,
approximately half of all pediatric neurosurgical cases
are treated at one center, while the other patients are
treated at the other three centers. Consequently, hospital
provider volumes of pediatric neurosurgery are quite low
for three out of the four treating hospitals.
To explore a possible effect of provider volume on long-
term outcome, we analyzed population-based data from the
Norwegian Cancer Registry and compared outcome after
surgery for central nervous system tumors diagnosed over
two decades, between March 1988 and April 2008.
Materials and methods
The Norwegian Cancer Registry
Reports to the Norwegian Cancer Registry are compulsory.
All neoplasms and certain precancerous lesions are to be
registered. The cancer registry receives data from three
sources: (1) Copies of all pathology and autopsy reports
from all Norwegian laboratories, (2) Clinical registration
forms from treating doctors, and (3) Information from
Statistics Norway about cause of death notified on death
certificates as well as vital status of all registered persons in
the cancer registry (if they are alive, dead, or have
emigrated). The compliance of the different data sources
is generally good. The unique 11-digit personal identifica-
tion numbers assigned to all Norwegian citizens ensure
tracking of patients and limit the risk of duplicate
registrations. From 1998, the cancer registry has also
acquired data files with discharge diagnoses (ICD-10 C or
D) on all patients treated for neoplastic disease in every
Norwegian hospital and outpatient clinic. When C- or D-
diagnoses are used in patients that are not registered in the
cancer registry, the clinician will receive reminders. The
completeness of patient registration has improved over the
years, and there are presumably no systematic biases in the
registered data. If patients undergo repeated surgery, or if an
autopsy is performed, the database is continuously updated
through submission of additional histological reports. The
Norwegian population of 4.7 million is stable with very
little migration. A study on the completeness of data
demonstrated that 93.8% of all central nervous system
tumors, including non-histologically verified cases [15].
Norwegian health regions, provider volumes, and adjuvant
treatment
Norway is divided into four geographical and administrative
so-called health regions (South-East, West, Middle, and
North) with one serving, university hospital with a complete
neurosurgical department offering pediatric neurosurgery in
each region. According to Statistics Norway, there were
975,125 children under the age of 16 in Norway by
January 1, 2009. Of these, 529,290 (54.3%) live in the
South-Eastern health region. Consequently, the case
volumes of pediatric tumors is about half the national
volume in one high-volume center while the other three
centers share the rest of the caseload. There are 1–3
neuropathologists at each university hospital, with exten-
sive collaboration between centers and frequent use of
second opinion reviews by the neuropathologist in other
hospitals. Adjuvant chemotherapy or radiotherapy is decided
by pediatric oncologists at the respective university hospitals.
However, there are national and/or international treatment
protocols for all malignant pediatric nervous system entities,
so there are presumably no major regional differences in
adjuvant treatment. Since 1998, there have been regular
nationalmeetingsbetweenneuropathologists,pediatricneuro-
surgeons, and pediatric oncologists to exchange experience
and ensure common practice.
Included patients and variables
The study aimed to include all children below the age of 16
operated for central nervous system tumors in Norway in
the 20-year period between March 1988 and April 2008. In
this period of two decades, 946 children below the age of
16 were diagnosed with central nervous system tumors in
Norway. Of these, patients diagnosed only based on clinical
examination or radiological methods were excluded (127
cases) together with patients where CNS tumor was
mentioned solely on the death certificate without further
documentation (0 cases). Cases diagnosed incidentally by
autopsy were excluded (three cases), leaving 816 patients
with histologically confirmed tumors. All patients were
followed until death or until April 30, 2009. Seven patients
emigrated and their data were censored at the time they left
the country. No patients were otherwise lost to follow-up.
Follow-up thus ranged from 1 to 21 years.
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sought to make comparative analyses between the high-
volume center and low-volume centers. Data from the three
low-volume centers, i.e., low-volume health regions, was
analyzed together.
Limitations in classifications of provider volume data
Data was analyzed based on both the health region where
the surgery was performed and on the geographical health
region the patient belonged to. This was done as both
methods are associated with some limitations due to cross-
over. Analyses based on the geographical origin of patients
is the most conservative approach and is equivalent to
intention-to-treat analyses in randomized controlled trials,
while analyses based on treating hospital is equivalent to
as-treated-analyses. In registry data, several prognostic
variables are unavailable. There is therefore a theoretical
potential for skewed distribution of prognostic factors that
cannot be controlled for. The risk of suffering from a brain
tumor with an unfavorable prognosis per se is, however,
presumably not dependent on one’s address. The conserva-
tive method of analyses based on a patient’s address
reduces the power to detect a statistical difference between
regions when there is cross-over, but this is of no concern if
statistical tests reveal a difference. Some patients were for
logistic reasons or due to local or regional hospital referral
traditions treated in a different center than they geograph-
ically belong to. Seventy-two patients from the low volume
had their surgery in the high-volume hospital. There are
several reasons for this cross-over in our study. Of these
cross-over patients, 48 (62%) belong geographically to the
county of Rogaland. The densely populated Stavanger
region in Rogaland County has traditionally referred all
neurosurgical patients to the National Hospital in Oslo
instead of Bergen, to which their patients geographically
belong. This has historical, logistical, as well as political
reasons. Also, 19 of the cross-over patients (26%) were
living in the three northernmost counties and were operated
in Oslo instead of Tromsø. The department in Tromsø was
established as late as 1986, only 2 years before the
beginning of our inclusion period. For historical reasons,
some doctors in the northernmost counties continued for
years to refer their neurosurgical patients to Oslo instead of
Tromsø. Due to transportational logistics, it is also easier
for many patients to travel to Oslo instead of Tromsø. The
fact that epilepsy surgery is centralized to the high-volume
south-eastern health region may also have implications on
where some lesions are treated. In addition, from 2001
patients have been allowed to choose themselves where to
be operated. However, very few decide to be operated in a
different health region than their own. If patients were
operated more than once and at different centers or
geographical health regions, data from the first operation
was used in the classification into high or low-volume
providers for the long-term survival analysis. One limitation
in the attempt to classify surgical volumes based on health
regions is the fact that until 1998, some children in the
South-Eastern region were also operated at a second
University Hospital in the South-Eastern region. The
patients from this low-volume center are thus analyzed
together with the high-volume data from Rikshospitalet
University Hospital.
Histopathological classification
In the Norwegian Cancer Registry, tumors were classified
according to ICD-7 until 1993. Thereafter, ICD-O-2 has
been used. Based on the ICD codes, we grouped the
operated tumor types into major groups in coherence with
the WHO classification of central nervous system tumors
[17].
Subgroup analyses
Most histopathological subgroups were too small to
perform any meaningful subgroup analysis. Benign lesions
or low-grade (WHO I or II) neuroepithelial tumors are for
the most part not associated with a significant medium-term
mortality rate. High-grade neuroepithelial tumors were,
however, analyzed separately as survival is dependent on
resection grades for these lesions [21], and as the overall
mortality is considerable.
Survival in the largest malignant histopathological
subgroup, namely PNET/medulloblastomas, is very much
dependent on remaining tumor mass after resection [1, 25,
27]. It was therefore of interest to conduct a separate
subgroup analysis for these tumors.
Ethics
The study was approved by the Regional Ethics Committee.
Statistics
Statistical significance level was set to 0.05. Data was
analyzed using SPSS 14.0 for Windows and R version
2.9.0. Cohen’s Kappa was used for assessing agreement
between the two classifications of provider volumes (by
geographical region or by health region in charge of the
initial treatment). Fisher's exact test and Chi-square test
were used in the analysis of significance in contingency
tables. Log-rank (Mantel-Cox) test was used for compari-
son of overall survival between the two provider volumes.
A statistician (ØS) verified the results of the presented
analyses. Multivariate Cox regression analysis with age as a
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namely PNET/medulloblastomas.
Results
Characteristics of low- and high-volume providing health
regions
Table 1 shows that the three smaller health regions counted
together have a lower surgical volume of pediatric central
nervous system tumors than the most populated health
region, both when analyzed by residential address of the
patient and when analyzed by region where the initial
treatment was given. It is further seen that some patients are
treated in a different health region than they geographically
belong to. Cohen’s kappa for agreement between the
geographical health region of residency and health region
providing the actual, initial treatment was 0.79, demon-
strating a substantial (but not perfect) agreement [14]. It
may also be deduced from Table 1 that the high-volume
health region seems to provide surgery for more central
nervous system tumors than expected from the number of
patients belonging to this region geographically. The
histopathological subgroups were for the most part quite
evenly distributed between the high- and low-volume
regions. However, choroid plexus tumors were more
frequently seen in patients living in the high-volume region
(p = 0.004).
Overall survival
As seen in Fig. 1, there were no overall differences in
survival between the low- and high-volume regions. An
overall statistical comparison between the two volume
groups with log-rank (Mantel–Cox) test resulted in
p=0.953 when analyzed by geographical belonging or
p=0.587 when analyzed by health region providing initial
surgery.
As seen in Table 2, 1-, 3-, and 5-year survival in
children operated for central nervous system tumors is
very similar in high- and low-volume regions. The wide
95% confidence intervals reflect the limited power of these
analyses.
Table 1 Distribution of histopathological subgroups by geographical region or by health region providing the initial treatment
Histopathology Belonging to which geographical health region;
n, (%)
Initial treatment in which health region;
n, (%)
Low-volume regions High-volume region Low-volume regions High-volume region
Pilocytic astrocytomas 74 (19.9) 77 (17.3) 66 (22.0) 85 (16.5)
Grade II astrocytomas 35 (9.4) 56 (12.6) 30 (10.0) 61 (11.8)
Anaplastic astrocytomas 4 (1.1) 5 (1.1) 4 (1.3) 5 (1.0)
Glioblastomas 14 (3.8) 11 (2.5) 14 (4.7) 11 (2.1)
Oligodendrogliomas 5 (1.3) 8 (1.8) 4 (1.3) 9 (1.7)
Mixed gliomas 10 (2.7) 16 (3.6) 9 (3.0) 17 (3.3)
Ependymal cell tumors 20 (5.4) 22 (5.0) 18 (6.0) 24 (4.7)
PNET/medulloblastomas 66 (17.7) 59 (13.3) 54 (18.0) 71 (13.8)
Other gliomas 14 (3.8) 15 (3.4) 12 (4.0) 17 (3.3)
Neuroepitelimatous neoplasms 23 (6.2) 30 (6.8) 17 (5.7) 36 (7.0)
Choroid plexus tumors 3 (0.8) 19 (4.3) 1 (0.3) 21 (4.1)
Pineal parenchymal tumors 8 (2.2) 2 (0.5) 7 (2.3) 3 (0.6)
Nerve sheath tumors 4 (1.1) 0 (0) 4 (1.3) 0 (0)
Meningiomas 8 (2.2) 3 (0.7) 7 (2.3) 4 (0.8)
Blood vessel tumors 5 (1.3) 2 (0.5) 4 (1.3) 3 (0.6)
Other mesenchymal non-meningothelial tumors 13 (3.5) 30 (6.8) 3 (1.0) 40 (7.8)
Primary intracranial adenomas/adenocarcinomas 5 (1.3) 10 (2.3) 5 (1.7) 10 (1.9)
Craniopharyngiomas 15 (4.0) 20 (4.5) 12 (4.0) 23 (4.5)
Germ cell tumors 1 (0.3) 2 (0.5) 1 (0.3) 2 (0.4)
Other tumors 35 (9.4) 39 (8.8) 24 (8.0) 50 (9.7)
Unspecified tumors 10 (2.7) 18 (4.1) 4 (1.3) 23 (4.5)
Total 372 (100) 444 (100) 300 (100) 516 (100)
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As seen in the subgroup analysis of high-grade neuro-
epithelial tumors displayed in Fig. 2, a comparison between
the two volume groups with log-rank (Mantel–Cox) test
resulted in p=0.178 when analyzed by geographical health
region residency or p=0.043 when analyzed by health
region providing initial surgery.
Figure 3 shows the Kaplan–Meier curves of survival in
PNET/medulloblastomas. There seems to be a survival
advantage both for patients living in or operated in the low-
volume health regions, p=0.042 and 0.023, respectively.
Estimated 5-year overall survival rates were 65±6% when
living in a low provider volume region versus 42 ±7%
when the patients' addresses were in the high-provider-
volume region. As the prognosis of PNET/medulloblasto-
mas is highly dependant on age, we also performed an
analysis of survival of PNET/medulloblastomas in a
multiple Cox regression model, correcting for age. In the
national protocols for treatment in the 20-year period of
inclusion, full-dose adjuvant therapy has generally only
been given to children older than 4 years old. Age was
therefore analyzed as a categorical variable; less than
4 years, or 4 years or older. The results are shown in
Table 3. Age less than 4 years was to no surprise an
independent risk factor for shorter survival, p=0.001. The
adjusted hazard ratio comparing morality in children less
than 4 years versus older children was 2.533, 95% CI
(1.491, 4.305). Provider volume of the geographical health
region the patient lived in was a significant factor in the
unadjusted analysis, p=0.045. The adjusted hazard ratio
was 1.798, 95% CI (1.057, 3.059) when the patient lived in
the high-volume health region as compared to the low-
volume regions, p=0.030. As presented in Table 4, the data
was also analyzed by the health region where the patient
received initial surgery. An age less than 4 years was still an
independent negative risk factor for survival, p<0.001. The
adjusted hazard ratio comparing mortality in children less
than 4 years versus older children was 2.572, 95% CI
(1.512, 4.373). Provider volume of health region where the
patient received initial surgery was a significant, indepen-
dent risk factor for survival, p=0.015. The adjusted hazard
ratio was 2.012, 95% CI (1.145, 3.533) when the initial
surgery was preformed in the high-volume health region
compared to elsewhere.
We also repeated all analyses after excluding the 72
patients that for some reason were centralized, i.e., operated
in the high-volume region while living in a low-volume
Fig. 1 Kaplan–Meier curves displaying cumulative survival in the 816 children with central nervous system tumors
Table 2 Overall survival after 1, 3, and 5 years, analyzed by which geographical health region the patients belong to or received initial treatment
in
Survival proportion and CI (95%) after Address in which geographical region Initial treatment in which region
Low-volume regions High-volume region Low-volume regions High-volume region
1 year 91 [88 to 94] % 91 [88 to 94] % 90 [87 to 93] % 91 [86 to 93] %
3 years 82 [78 to 85] % 81 [77 to 85] % 82 [78 to 86] % 82 [79 to 85] %
5 years 79 [75 to 83] % 78 [74 to 82] % 79 [74 to 83] % 79 [75 to 82] %
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lesions, contrary to our belief, are in fact already to some
extent centralized today. Data from these analyses is not
shown as hazard ratios and significance levels were
practically unchanged.
Since requestedinthe reviewprocess ofthispaper,wealso
attempted to explore survival in pure medulloblastomas
separately. Before 1993, medulloblastomas and other PNETS
have been classified together according to the ICD-7
classification system, not allowing for an identification of
the pure medulloblastomas. From 1993, location of lesions
has been registered according to the ICD-O2, enabling a
separation of supratentorial PNETS, overlapping PNETS and
unspecified/unclassified PNETS from the pure medulloblas-
tomas affecting the cerebellum or brain stem. Sixty-seven
pure medulloblastomas that were registered since 1993 were
identified in our data set. In thissmall subgroup of tumors, we
still observed a tendency towards a survival advantage if
patients were living in the low-volume health regions (n=34),
p=0.062. In a Cox regression model, the patient's address
was an independent risk factor for survival, after correcting
for age and location of lesion (pure medulloblastoma vs.
other), HR 2.2, p=0.015. Curiously, we did not observe a
statistically significant difference in survival between “pure”
medulloblastomas and other PNETS in Norway treated since
1993, (p=0.492).
Discussion
Surgical volumes of pediatric tumors in the Norwegian
neurosurgical departments vary markedly as one of the
centers has higher surgical volumes than the other three
treating departments counted together. Inspired by an
ongoing national debate about centralizing surgery for
central nervous system tumors in children, we conducted
an analysis of long-term survival in low-volume regions
versus the high-volume region. We observed no overall
Fig. 2 Kaplan–Meier curves displaying cumulative survival in the 230 children with high-grade neuroepithelial tumors
Fig. 3 Kaplan–Meier curves displaying cumulative survival in the 125 children with PNET/medulloblastomas
1224 Acta Neurochir (2011) 153:1219–1229survival advantage associated with high surgical volumes.
This may of course be a type II error due to lack of
statistical power. However, as the analysis presumably
included practically all central nervous system tumors of
children treated in Norway over a period of two decades,
this power problem is not solvable. The subgroup analysis
in high-grade neuroepithelial tumors revealed an unexpect-
ed tendency of lower survival associated with the high-
provider-volume region. The largest subgroup of malignant
brain tumors in children, namely PNET/medulloblastomas,
was analyzed separately. Living in and/or receiving
treatment in the high-provider-volume health region was
independently associated with inferior survival in these
patients. Estimated 5-year overall survival rates were 65±
6% versus 42±7%, when analyzed by geographical
belonging. A study from the National Cancer Institute’s
Surveillance Epidemiology and End Results (SEER) data-
base reports of 56% 5-year survival in PNET/medulloblas-
tomas in patients less than 20 years old treated in the period
between 1985 and 1998 [19]. However, after the develop-
ments in chemotherapy in the later years, survival rates
have improved considerably [20]. Published studies often
use different inclusion criteria in terms of patient age, tumor
location, and risk stratification, making comparisons of
results difficult. Generally, few modern series report of 5-
year survival rates of less than 50%.
The role of the volume–outcome relationship is much
discussed in surgery as the true nature of the volume–
outcome relationship is not yet fully understood. The
“practice-makes-perfect” hypothesis [18] is supported by
numerous studies of many procedures that report an overall
tendency toward better outcome if treated in high-volume
hospitals or by high-volume surgeons. Another explanation
of the observed volume–outcome relationship is the
“selective-referral hypothesis” [18], which suggests that
health care institutions or surgeons with better outcomes
may receive higher patient volumes due to an increase in
referrals. Or likewise, high-volume hospitals may have a
greater tendency to attract surgeons who are receiving
better results. It is, however, also known that there may be
considerable variability in patient outcome, even among
high-volume surgeons [8]. Further, several low-volume
surgeons or hospitals report excellent outcomes. Higher
case volumes may therefore not automatically result in
better outcome, and case volume may perhaps serve as a
surrogate marker for several interacting factors in complex
medical settings. By analyzing data based on geographical
belonging, there is no concern for referral bias in our study.
Several limitations are common in studies of provider
volume and outcome in brain tumor surgery. Available
studies are almost exclusively American [3–6, 10, 11, 16,
22] and tend to utilize many of the same administrative data
sources with the same strengths and limitations. Frequent
weaknesses are failure to control for potential confounders,
lack of validated, long-term end-points, and lack of analysis
based on surgeons’ individual surgical volumes. Further,
interest bias may affect such publications as publications
mostly originate from high-volume centers. Results may
also not necessarily apply to countries where health care is
organized differently. Little is also known about how
regional differences in common outcome measurements
such as in-hospital mortality and early morbidity affect
long-term results. Further, it is not known if reasonable
patient volumes are associated with poorer results than very
high patient volumes, or if the benefit of surgical
experience reaches a plateau. One American study reports
that pediatric neurosurgeons are more likely than general
neurosurgeons to extensively remove malignant pediatric
brain tumors [2]. However, the pediatric neurosurgeons all
had practiced for a number of years to obtain the
subspecialty, while there was a wider spectrum of experi-
ence among the general neurosurgeons in the study. Thus,
the observed difference may be a result of differences in
neurosurgical experience, and not necessarily due to differ-
ences in experience with pediatric cases. Many of the
general neurosurgeons in the study also had very low
Table 3 Cox regression analysis of age and patient address as a predictor for survival. Hazard ratios (HR) and 95% confidence intervals (CI) are
shown
Variables in the regression model Unadjusted HR 95% CI p value Adjusted HR 95% CI p value
Age less than 4 years 2.455 1.446 to 4.167 0.001 2.533 1.491 to 4.305 0.001
Address in the high-volume health region 1.722 1.012 to 2.931 0.045 1.798 1.057 to 3.059 0.030
Table 4 Cox regression analysis of age and treating health region as a predictor for survival. Hazard ratios (HR) and 95% confidence intervals
(CI) are shown
Variables in the regression model Unadjusted HR 95% CI p value Adjusted HR 95% CI p value
Age less than 4 years 2.455 1.446 to 4.167 0.001 2.572 1.512 to 4.373 <0.001
Treated in the high-volume health region 1.900 1.082 to 3.336 0.025 2.012 1.145 to 3.533 0.015
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mortality was lower when craniotomies in children were
performed at high-volume hospitals and by high-volume
surgeons [22]. However, 25% of the hospitals treated only
1–4 pediatric brain tumors annually and 22% of the
surgeons only operated one pediatric case per year.
Conversely, a survival analysis of children with primary
malignant brain tumors in England and Wales found no
regional differences [24].
Pediatric intracranial tumors are very diverse both in
locations and histopathology, thereby limiting the possibil-
ity of obtaining extensive personal surgical experience for
most entities, even in the larger centers. Further, as both
clinical and part-time academic positions often are more
prevalent in the larger centers, the higher institutional
volumes may not always be reflected in the personal
experience of the individual surgeons. Thus, even if one
may believe in a potential volume–outcome relationship in
most medical procedures, it may still not be a significant
factor in pediatric brain tumor operations, since personal
volumes (and thereby “practice”) is difficult to obtain due
to the diversity and rarity of such lesions. As seen in
Table 1, there was for example only 35 craniopharyngiomas
in children in treated Norway over a period of 20 years, or
only 1.75 cases per year nationally. Thus, for many pediatric
neurosurgicaltumors,theoperatingsurgeonoftenpresumably
n e e d st or e l ym o r eo n“transferable skills” based on
experience from operations in the same anatomical region or
caseswithsimilarhistopathology,ratherthanrecentanddirect
experience from exact similar cases. Hydrocephalus is by far
the most common pediatric neurosurgical condition in terms
of the number of operations. Perhaps a neurosurgeon
primarily engaged in difficult adult tumors and various
infratentorial procedures who also operates a few pediatric
tumors may achieve results as good as a pediatric neurosur-
geonwhoperformsa lot ofshunt surgeriesinadditiontoa fair
amount of pediatric tumor resections.
Several factors and professions contribute to the final
result for children with brain tumors (skill of neuroradiol-
ogists, surgical technique, surgical skills, frequency of
complications, treatment of medical and surgical complica-
tions, anesthesiological skills, intensive-care treatment,
adherence to adjuvant treatment protocols, quality of the
rehabilitation service, closeness of follow-up, frequency of
repeated surgery, accuracy of neuropathologists, etc). Most
factors are not easily quantifiable, but may still affect
outcome and even survival. We believe that the potential
importance of surgical case volumes may be greatly
overshadowed by all the other factors that are important
for the results in these patients. As exemplified in our
results, just counting the number of operations at a center,
as often is the case in debates about centralization, is not
necessarily a valid measure for quality of treatment.
In our study, we observed no benefit from living in the
most populated health region or receiving treatment in the
health region with the highest case volumes. On the
contrary, a subgroup analysis of PNET/medulloblastomas
surprisingly indicated that both living in and receiving
treatment in the high-volume region was associated with
inferior survival. Theoretically, there may be several
explanations for the observed differences in our study:
differences in adjuvant therapy, differences in histopatho-
logical classifications due to inter-observer variability,
differences in surgical skills or surgical technique, unknown
differences in tumor biology, for example due to differences
in ethnical compositions of treated populations, or simply
due to statistical chance. As seen from the p values, the
likelihood of the discrepancy in medulloblastoma/PNET
survival to be a result of mere statistical chance is in the
range between 1.5 and 4.5%. Adjuvant chemotherapy or
radiotherapy is decided by pediatric oncologists at the
respective university hospitals. However, there are national
or international treatment protocols for malignant pediatric
entities so there are presumably no significant regional
differences in adjuvant treatment. Still, adherence to
protocols may theoretically vary. For more than a decade,
there have been regular national meetings between
neuropathologists, pediatric neurosurgeons, and pediatric
oncologists to exchange experience and ensure common
practice. Divergence in treatment strategies or tumor
classification is very seldom. There is an extensive
collaboration between centers and frequent use of
second-opinion reviews by neuropathologists from other
centers to ensure agreement in classifications. Still, to be
acknowledged, unknown variations in classification represent
a potential significant threat to our subgroup analyses, since
therewasnouniformmicroscopicreviewofincludedpatients.
Controversies relating to the pathobiology and classification
of central nervous system primitive neuroectodermal tumors
have plagued neuropathologists for years. Even though
differences in molecular genetics and prognosis are reported,
given that PNETS and medulloblastomas are histologically
identical, it is for now recommended that studies provide
analyses for the two entities combined to reduce the bias of
misclassification [19]. We nevertheless attempted to also
analyze a recent cohort of “pure” medulloblastomas sepa-
rately, since a location variable was available in the later
years. Curiously, we did not find a statistical significant
difference in survival between “pure” medulloblastomas and
other PNETS in Norway treated since 1993. This could
perhaps be due to the lack of power associated with the
small sample sizes in such subgroup analyses. We observed
a tendency towards regional differences in survival in pure
medulloblastomas treated since 1993, but these were
statistically just non-significant. In a regression model,
patient address was however an independent, significant
1226 Acta Neurochir (2011) 153:1219–1229factor when correcting for site of lesion and age in this
subgroup. It therefore seems unlikely that skewed distribu-
tions in the site are responsible for the regional differences in
survival observed in PNETs/medulloblastomas. Still, since
the Norwegian Cancer Registry has no information about
tumor sizes, actual resection grades, or other factors
associated with survival, it is not known that the
compared groups are completely balanced. However, the
analysis based on the patients’ addresses is quite
conservative, and would presumably ensure a balanced
composition of patient groups, presupposing that inci-
dence rates are not geographically unbalanced. As seen
in Table 1, the size of the medulloblastoma/PNET group is
slightly bigger in the low-volume regions, suggesting a
possible variance in classification between centers. How-
ever, the subgroup analysis in high-grade neuroepithelial
tumors, a subgroup where all true medulloblastomas and
other PNETS presumably are included, also indicated a
tendency towards inferior survival in the health region
with higher case volumes. Nevertheless, due to the above-
mentioned factors, especially the potential for misclassifi-
cation bias, we suggest that the finding in the medullo-
blastoma/PNET group should be interpreted with caution.
Even so, these results call for that tumor classification and
patient outcome should be evaluated on a national level in
these patients.
A weakness of our study is the potential for skewed
distributions of histopathological subgroups due to inter-
observer variability among the different neuropathologists.
This could naturally affect results from subgroup analyses,
as already discussed. We observed an unexpected skewed
distribution of choroid plexus tumors between the health
regions in the Norwegian Cancer Registry data. We cannot
explain this finding, but is possibly due to differences in
reporting to the cancer registry since in some instances
these tumors may have been classified as non-reportable
blood vessel tumors. Other causes could be statistical
chance (and multiple significance testing), variance in
classification, or due to differences in initial treatment
strategy (expectancy, gamma knife treatment, shunt surgery,
or resection/biopsy). We only included histologically
confirmed tumors in our study. Excluding the five
malignant choroid plexus tumors in the data did alter
the p values in the high-grade neuroepithelial tumor
cohorts, but not much. The p value changed to p=0.064;
thus still a tendency towards a better outcome if high-
grade neuroepithelial tumors were treated in the low-
volume centers. However, to be acknowledged, the patient
material of 816 quite diverse cases may be vulnerable due
to its limited power. The tendency of inferior survival in
high-grade neuroepithelial tumors treated in the high-
volume center is eliminated if PNET/medulloblastomas
are excluded from the analysis; thus leaving the difference
in PNETS/medulloblastoma survival as the only unex-
plained finding.
The strength of our study is the high-quality data from
the Norwegian Cancer Registry. Very few studies on
provider volumes and outcome can provide population-
based data with high degree of inclusion, and long-term
follow-up. Surgical case series without adequate controls
from single institutions are flourishing in the neurosurgical
literature. Yet, it is known that studies with excellent
outcome are more likely to be published. Evaluation of own
data may further be associated with bias. It has for example
been reported that the true surgical mortality rates are much
higher than published in operative series [23]. Thus,
community-based prospective registration of all patients
who underwent surgery, providing a sampling frame free
from publication and sampling bias is encouraged [26]. The
unselected population-based inclusion in our study ensures
high external validity and unbiased selection of patients.
Still to be acknowledged, population-based studies may be
associated with some difficulties as several prognostic
variables often are unavailable. However, as data was also
analyzed by patients’ geographical belonging, large varia-
tions in prognostic factors between the two provider
volume groups are not likely. We still adjusted for age
and in part for tumor location in the analysis of results in
PNETs/medulloblastomas. Preferably, we should also have
been able to correct for other known prognostic factors such
as tumor size, prevalence of micro-metastases, adherence to
adjuvant treatment protocols, re-operation rates, histopath-
ological features, etc. Unfortunately, such variables were
not available to us.
The main weakness of our study is the relatively low
power, which is due to small population of Norway. As
mentioned in the Materials and methods section, pediat-
ric neurosurgery was also performed at a second
university hospital in the South-East region up until
1998. This pollutes the high-volume health region in our
analysis with some operations from this lower-volume
hospital. However, the tendency in the results is not
different in the last 10 years as compared to the first
10 years of the study period (data not shown). Thus, this
weakness in data classification is presumably of no major
concern for the conclusion. Like most studies, we were
unable to analyze data based on operating volumes of the
individual surgeons. Some may argue that the case
volume of the largest Norwegian neurosurgical center is
still quite low. Our conclusions may therefore not be
valid in countries where pediatric neurosurgeons have
much higher caseloads. However, for most histopatho-
logical subgroups and tumor sites, the volume per
pediatric neurosurgeon is low at any center in the world,
due to the low incidence and the diversity of such
lesions.
Acta Neurochir (2011) 153:1219–1229 1227Despite some weaknesses, it seems safe to conclude that
provider volume is no proxy for quality of care in pediatric
central nervous system tumors in Norway. Some may believe
that data aggregated from hundreds of neurosurgical centers
would have demonstrated a trend towards better long-term
outcome in high-volume centers. However, such possible
findings may not necessarily be extrapolated across national
borders or to small regions with only a few centers. There are
many outliers in pooled analysis of data on provider volumes,
andsurgicalcasevolumeisonlyone ofmanypotentialfactors
that may influence patient outcome.
Conclusions
Inspired by an ongoing debate about centralization, we aimed
to explore if the low-volume neurosurgical centers are
associated with inferior survival in children with central
nervous system tumors. In this population-based study of all
central nervous system tumors in children operated over a
period of two decades, we found no evidence of improved
long-term survival in the high-provider-volume region. On
thecontrary,asubgroupanalysisfoundthatsurvivalinPNET/
medulloblastomaswassignificantlybetteriftreatedelsewhere
than in the most populated health region with the highest case
volumes. We have no explanation for this finding. One
should, however, be careful of interpreting this directly as a
symptom of quality of care, as there may be unseen
confounders. Our study demonstrates that provider case
volume may serve as an axiom in debates about centralization
of cancer surgery while perhaps much more reliable and valid
but less quantifiable factors are important for the final results.
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Comment
This is an interesting study looking to see if outcomes of CNS tumors in
children correlate with the caseload in Norway. The data is quite solid
because it is based on a very organized and reliable reporting system.
The conclusions are probably contrary to what was to be expected.
There was no demonstrable advantage of being operated or having
adjuvant neuro-oncological treatments performed in higher-volume
centers. There was actually a slight opposite tendency.
The authors underscore most difficulties with the study. Degree of
resection and differences in surgical skills all seem to be attenuated in
a study of this span. Diverse tumor biology based on ethnical grounds
is possible but not plausible. How are we then to interpret these
findings and what should be made relevant? Pediatric neurosurgery
has been an organized subspecialty in neurosurgery for many years
now and one which requires an extra period of training beyond what is
currently comprised within general residency training. This may
justify an average longer surgical experience for pediatric neuro-
surgeons as compared to across-the-board general neurosurgeons. This
being the case, this factor may contribute to dilute differences between
higher- and lower-volume centers. Also, high- and low-volume needs
necessarily to be defined especially for pediatric CNS tumors. It
should be defined not only for centers but also for single surgeons
performing surgery. Factors such as resident training (and the part we
let them play in surgery), which usually occurs in higher-volume
centers may also be a consideration (as for other types of surgery).
Thirdly, outcomes must also be tied up with the types of tumors
treated. The authors have justly opted to separately analyze the group
of PNET/medulloblastomas, a group where degree of resection is of
the utmost importance. We have, however, no information regarding
this issue. The type of surgery, or else the difficulty of each surgical
act as it relates to the underlying tumor, is also a factor that is not
possible to factor in. Resection of a medulloblastoma is of extreme
importance but usually a less difficult task than the resection of a
craniopharyngioma or the odd pineal region tumor.
All in all, what the study seems to point at is that the sheer number
of cases done per year is certainly not the single variable influencing
operative and treatment outcomes for these and other nosological
entities. It is also not known for each specific area of expertise within
neurosurgery what the boundary is that draws the line between a
surgical practice self-sufficient to comply to the state-of-the-art
numbers of M&M and one which does not meet these caseload
criteria.
Manuel Cunha e Sa
Almada, Portugal
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